Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human Antithrombin III for prophylactic treatment in congenital antithrombin III deficiency
CTR20244596Phase 3Active
- Sponsor
- Sichuan Yuanda Shuyang Pharmaceutical
- Start
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of antithrombin III in congenital antithrombin deficiency (ATD) (2 arms), sponsored by Sichuan Yuanda Shuyang Pharmaceutical. Primary endpoints: Stage 1 single-dose pharmacokinetic parameters and Incidence of thrombotic events. Started Mar 2025; status: active.
02
Drugs
antithrombin III
03
Conditions
congenital antithrombin deficiency (ATD)
Beyond the preview
Go deeper on CTR20244596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244596.